Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
A holder of PCRX common stock filed a notice to sell 13,137 shares under Rule 144. The shares are common stock to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/02/2026 and aggregate market value of 269,702.61.
The securities were acquired as restricted stock vesting from the issuer on 02/01/2026, treated as compensation. The filing notes that there were 43,021,275 shares of this class outstanding at the time, providing baseline context for the planned sale size.
Pacira BioSciences, Inc. director Samit Hirawat received a grant of stock options on January 27, 2026. The award covers 39,291 stock options with an exercise price of $19.85 per share, held directly, and represents a right to buy common stock.
According to the vesting terms, one-third of the options vest on the first anniversary of the grant date. The remaining options vest in equal monthly installments over the following two years, as long as the director continues in service. The options expire on January 27, 2036.
Pacira BioSciences, Inc. director Samit Hirawat filed an initial ownership report on Form 3. The filing states that, as of the event date of 01/27/2026, no securities of Pacira BioSciences are beneficially owned. This is an administrative disclosure of current holdings status.
Pacira BioSciences, Inc. expanded its Board of Directors from nine to ten members and appointed Dr. Samit Hirawat as a Class III director, effective immediately on January 27, 2026. He will also serve on the Board’s Science and Technology Committee.
Dr. Hirawat will receive Pacira’s standard compensation for non-employee directors. The Board determined that he qualifies as an independent director under Nasdaq’s listing standards. The company later issued a press release on January 28, 2026 to publicly announce his appointment.
DOMA Perpetual Capital Management LLC, which says it beneficially owns approximately 6.83% of Pacira BioSciences, Inc. common stock, plans to run a dissident slate of three independent director candidates at Pacira’s 2026 annual shareholder meeting. DOMA states that Pacira’s board should pursue an immediate sale of the company and criticizes current executive compensation and general spending as “exorbitant and unmerited,” while also questioning whether the board has provided appropriate fiduciary oversight.
DOMA and affiliated entities, including DOMA Perpetual LO Equity Master Fund LP, DOMA Perpetual Partners GP LLC, Reliability LLC and Pedro Escudero, intend to solicit votes using a WHITE proxy card and will file a detailed proxy statement with the SEC. The group collectively may be deemed to beneficially own several million Pacira shares through various entities, and it urges Pacira stockholders to review its forthcoming proxy materials when available.
Pacira BioSciences, Inc. filed a current report stating that it has issued a press release with its preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company is sharing an early view of its 2025 revenue performance before final audited results are available.
The press release, dated January 8, 2026, is included as Exhibit 99.1. Pacira notes that this revenue information is being furnished rather than filed under securities laws, which limits how it is treated for certain liability and incorporation-by-reference purposes.
Pacira BioSciences Chief Medical Officer Jonathan Slonin reported an automatic share withholding related to equity compensation. On January 2, 2026, 381 shares of Pacira common stock were withheld at $24.46 per share to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin beneficially owned 178,523.175 shares of Pacira common stock, which includes 537.166 shares acquired through the company’s employee stock purchase plan in December 2025. This filing reflects routine tax and ownership reporting rather than an open-market trade.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported two stock transactions in early January 2026. On January 2, 2026, 159 shares of Pacira common stock were withheld by the company at $24.46 per share to cover tax obligations when a restricted stock unit award vested. On January 5, 2026, Riker sold 1,416 shares of common stock at a price of $24.24 per share under a pre‑established Rule 10b5‑1 trading plan. After these transactions, Riker directly owned 59,064.242 shares of Pacira common stock, which includes 1,075.242 shares acquired through the company’s employee stock purchase plan in December 2025.
Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan. On 12/31/2025, he obtained 402.268 shares of Pacira common stock at a price of $10.763 per share under the issuer's employee stock purchase plan.
After this transaction, Teehan directly beneficially owned a total of 54,402.268 shares of Pacira common stock, reflecting his ongoing equity participation as an executive officer.
Pacira BioSciences, Inc. (PCRX) reported an insider stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 3,960 shares of Pacira common stock at a price of $24.09 per share, according to a Form 4 filing. After this transaction, the officer directly beneficially owned 178,367.009 shares of Pacira common stock.
The filing states that this sale was carried out under a Rule 10b5-1 trading plan, which is a pre-arranged plan for buying or selling stock that is intended to comply with securities regulations and provide an affirmative defense against insider trading claims.